Spero Therapeutics, Inc.
Spero Therapeutics is a clinical-stage biopharmaceutical company developing SP001, a third-generation Fc-silent anti-CD40L monoclonal antibody for IgG4-related disease and other immune-mediated conditions.
8-KNov 12Latest SEC filing
Nov 12Latest story
November 2026
October 2026
August 2026
July 2026